You have 9 free searches left this month | for more free features.

Chronic Myelomonocytic Leukemia

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Chronic Myelomonocytic Leukemia Trial in Houston (Azacitidine, Tamibarotene, Venetoclax)

Not yet recruiting
  • Chronic Myelomonocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 10, 2023

Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 Trial in Houston

Active, not recruiting
  • Chronic Myelomonocytic Leukemia-0
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 18, 2023

Chronic Myelomonocytic Leukemia Trial in Indianapolis (CD4CAR)

Not yet recruiting
  • Chronic Myelomonocytic Leukemia
  • CD4CAR
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
Oct 2, 2023

MDS, Chronic Myelomonocytic Leukemia Trial in Tianjin (BC3402, Azacitidine)

Recruiting
  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital, Chinese Acade
Jul 30, 2023

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Canakinumab
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

Not yet recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Subcutaneous azacitidine
  • Oral decitabine/cedazuridine
  • Newcastle, New South Wales, Australia
    Calvary Mater Newcastle
May 29, 2023

Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia Trial in Charlottesville (Tagraxofusp)

Recruiting
  • Myelofibrosis
  • +2 more
  • Charlottesville, Virginia
    Danyelle Coley
Jan 18, 2023

Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia Trial in Rochester (Biospecimen

Recruiting
  • Recurrent Chronic Myelomonocytic Leukemia
  • Refractory Chronic Myelomonocytic Leukemia
  • Biospecimen Collection
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)

Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
Oct 20, 2022

Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Trial (AMG 176, Azacitidine)

Not yet recruiting
  • Higher Risk Myelodysplastic Syndrome
  • Chronic Myelomonocytic Leukemia
  • (no location specified)
Jul 29, 2022

Chronic Myelomonocytic Leukemia, Leukemia Trial in United States (Ruxolitinib)

Active, not recruiting
  • Chronic Myelomonocytic Leukemia
  • Leukemia
  • Tampa, Florida
  • +4 more
Nov 11, 2022

Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML) Trial in Seoul

Active, not recruiting
  • Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023

MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)

Recruiting
  • Myelodysplastic Syndromes
  • Myeloproliferative Chronic Myelomonocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022

Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial

Recruiting
  • Recurrent Chronic Myelomonocytic Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

Myelofibrosis, Chronic Myelomonocytic Leukemia Trial in Canada, United States (SL-401)

Active, not recruiting
  • Myelofibrosis
  • Chronic Myelomonocytic Leukemia
  • Duarte, California
  • +9 more
Jan 24, 2023

Chronic Myeloid Leukemia Trial in France (Venetoclax)

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Amiens, France
  • +14 more
Mar 3, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid

Active, not recruiting
  • Acute Myeloid Leukemia
  • +9 more
  • Los Angeles, California
  • +5 more
Jan 27, 2023

MDS, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia Trial (RP7214)

Not yet recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • (no location specified)
Aug 17, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts Trial (Biospecimen

Not yet recruiting
  • Chronic Myelomonocytic Leukemia
  • +3 more
  • Biospecimen Collection
  • +3 more
  • (no location specified)
Oct 27, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)

Recruiting
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 Trial in Houston

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 4, 2022

Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia Trial in Tianjin (LILRB4 STAR-T cells injection)

Not yet recruiting
  • Acute Myelogenous Leukemia
  • Chronic Myelomonocytic Leukemia
  • LILRB4 STAR-T cells injection
  • Tianjin, Tianjin, China
  • +1 more
Feb 12, 2023

Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Houston (DSP107, Azacitidine, Venetoclax)

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • DSP107
  • +2 more
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center, Department of
Nov 13, 2022

Leukemia, Leukemia, Myeloid, Monocytic Leukemia Trial in Palo Alto (Enasidenib mesylat dose escalation)

Recruiting
  • Leukemia
  • +2 more
  • Enasidenib mesylat dose escalation
  • Palo Alto, California
    Stanford Cancer Institute
May 12, 2022